文献速递腹部MRCT

基于肿瘤生长速率的LI-RADS阈值增长可提高≤3.0 cm肝细胞癌的诊断准确性

LI-RADS threshold growth based on tumor growth rate can improve the diagnosis of hepatocellular carcinoma ≤ 3.0 cm.
PubMed 文献 · Eur Radiol · 2023-08-17

该回顾性研究纳入370例患者508个≤3.0 cm局灶性实性病灶,比较基于肿瘤生长速率(≥10%/月、≥20%/月、≥30%/月)的改良阈值增长与LI-RADS v2018原始阈值增长(≤6个月内增大≥50%)诊断肝细胞癌的准确性。结果显示,TG-10%较原始阈值增长显著提高准确性(85.0% vs. 80.7%,p<.001)和敏感度(79.0% vs. 72.5%,p<.001),特异度无显著差异(96.6% vs. 96.6%,p>.999)。

要点

  • TG-10%(≥10%/月)较LI-RADS v2018原始阈值增长显著提高诊断准确性(85.0% vs. 80.7%,p<.001)。
  • TG-10%敏感度高于原始阈值增长(79.0% vs. 72.5%,p<.001),特异度无显著差异(96.6% vs. 96.6%,p>.999)。
  • 在334个肝细胞癌中,TG-10%的阈值增长出现频率显著高于原始阈值增长(53.3% vs. 18.0%,p<.001)。

核心结论

  • 基于肿瘤生长速率≥10%/月的阈值增长(TG-10%)通过检出因短期随访被低估的额外肝细胞癌,提高了LI-RADS诊断肝细胞癌的敏感度。

研究设计与样本

  • 回顾性研究,纳入370例患者共508个≤3.0 cm的局灶性实性病灶,比较术前MRI与既往CT/MRI上的病灶大小。

关键影像表现/征象

  • 由三名阅片者分别在既往CT/MRI和本次MRI上测量每个病灶的大小。
  • 肿瘤生长速率定义为病灶大小每月变化的百分比。

诊断标准与关键数值

  • 原始阈值增长定义为≤6个月内病灶增大≥50%。
  • 改良阈值增长基于肿瘤生长速率≥10%/月(TG-10%)、≥20%/月(TG-20%)、≥30%/月(TG-30%)。
  • 比较LI-RADS 5类肝细胞癌的诊断准确性:TG-10%为85.0% vs. 原始阈值增长80.7%(p<.001)。
  • TG-20%准确性81.3% vs. 原始80.7%(p=.404),TG-30%准确性79.3% vs. 原始80.7%(p=.052),均无显著差异。
  • TG-10%敏感度79.0% vs. 原始72.5%(p<.001),特异度96.6% vs. 96.6%(p>.999)。

临床应用与阅片要点

  • 作者指出,基于肿瘤生长速率的阈值增长可通过提高LI-RADS敏感度,在肝细胞癌诊断中具有临床实用价值。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: Despite the revision of threshold growth (TG) in the Liver Imaging Reporting and Data System (LI-RADS) version 2018, the appropriate time period between the two examinations for TG has not been determined. We compared the accuracy of LI-RADS with TG based on tumor growth rate for the diagnosis of hepatocellular carcinoma (HCC) with that of LI-RADS v2018 based on the original TG.

METHODS: Patients who underwent preoperative MRI for focal solid lesions (≤ 3.0 cm) were retrospectively evaluated. Three readers measured the size of each lesion on prior CT/MRI and index MRI, with tumor growth rate defined as the percent change in lesion size per month. In addition to the original TG (≥ 50% size increase within ≤ 6 months), the modified TG based on tumor growth rates ≥ 10%/month (TG-10%), ≥ 20%/month (TG-20%), and ≥ 30%/month (TG-30%) were evaluated. The accuracies of these evaluation methods for LI-RADS category 5 HCC were compared using generalized estimation equations.

RESULTS: A total of 508 lesions from 370 patients were evaluated. Compared with LI-RADS v2018 with the original TG, the accuracy of LI-RADS with TG-10% was significantly higher (85.0% vs. 80.7%, p < .001), whereas the accuracies of LI-RADS with TG-20% (81.3% vs. 80.7%, p = .404) and TG-30% (79.3% vs. 80.7%, p = .052) were not significant. The sensitivity of LI-RADS with TG-10% was higher than that of LI-RADS v2018 (79.0% vs. 72.5%, p < .001), whereas their specificities were not significantly different (96.6% vs. 96.6%, p > .999).

CONCLUSION: TG-10% improved the sensitivity of LI-RADS by detecting additional hepatocellular carcinomas underestimated due to short-term follow-up.

CLINICAL RELEVANCE STATEMENT: Threshold growth based on tumor growth rate can be clinically useful in the diagnosis of hepatocellular carcinoma, by improving the sensitivity of LI-RADS.

KEY POINTS: • The diagnostic accuracy of Liver Imaging Reporting and Data System (LI-RADS) v2018 was not significantly affected by the time interval between prior and index assessments of threshold growth. • In the 334 hepatocellular carcinomas, the frequency of threshold growth was significantly higher using tumor growth rate ≥ 10%/month (TG-10%) than original threshold growth (53.3% vs. 18.0%, p < .001). • Compared with LI-RADS v2018 with the original threshold growth, LI-RADS with TG-10% had significantly higher accuracy (85.0% vs. 80.7%, p < .001) and sensitivity (79.0% vs. 72.5%, p < .001) but a similar specificity (96.6% vs. 96.6%, p > .999).

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Jeong B, Choi SJ, Choi SH, et al. LI-RADS threshold growth based on tumor growth rate can improve the diagnosis of hepatocellular carcinoma ≤ 3.0 cm. Eur Radiol. 2023. PMID: 37589898. doi:10.1007/s00330-023-10092-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。